You are here

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

Last updated on December 5, 2018

FOR MORE INFORMATION
Study Location
J&S Studies
Bryan, Texas, 77802 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Onychomycosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- A witnessed, signed informed consent approved by Institutional Review Board

- Male or female of any race at least 18 years of age but not older than 65 years of age
at the time of screening

- Body Mass Index between 18.5 and 35, inclusive

- Onychomycosis involving > 80% of both great toenails, as determined by visual
inspection after the nail has been trimmed

- Each great toenail possess a combined thickness of the nail plate and nail bed > 3 mm

- At least six additional toenails with clinical diagnosis of onychomycosis

- A positive KOH wet mount for at least one great toenail

- If subject is a female of childbearing potential, must be using a highly effective
method of birth control (e.g. implants, injectables, combined oral contraceptives,
some intrauterine contraceptive devices) during the study

- Considered reliable and capable of understanding his/her responsibility and role in
the study

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of allergy to any of the test product(s) or any components in the test
product(s) or history of hypersensitivity or allergic reactions to any of the study
preparations as described in the Investigator's Brochure

- Clinically significant laboratory abnormalities that would interfere with the conduct
or interpretation of the study or jeopardize his/her safety

- Diabetes mellitus requiring treatment other than diet and exercise

- Unwilling to refrain from the use of nail cosmetics such as clear and or colored nail
lacquers from the screening visit until the end of the study

- Nursing, pregnant or planning to become pregnant during the study

- Has not undergone the specified washout period(s) for the following topical
preparations or does the subject require the concurrent use of any of the following
topical medications:

1. Topical antifungal applied to the feet (does not include antifungals for
treatment of T. pedis during the study: 4 weeks

2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks

- Has not undergone the specified washout period(s) for the following systemic
medications or does the subject require the concurrent use of any of the following
systemic medications:

1. Corticosteroids (including intramuscular injections): 2 weeks

2. Antifungals for treatment of onychomycosis or any systemic antifungal with known
activity against dermatophyte: 24 weeks

3. Systemic immunomodulators: 4 weeks

- Received treatment of any type for cancer within the last 6 months

- History of any significant internal disease

- Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
disorders, onychogryphosis, trauma to the nail(s) to be treated

- AIDS or AIDS related complex

- History of street drug or alcohol abuse

- Donated or lost blood, or participated in a clinical study which involved the
withdrawal of a large volume of blood (480 mL or more), during the six week period
preceding study initiation

- Donated plasma during the two week period preceding study initiation

- Participated in any other trial of an investigational drug or device within 60 days
prior to enrollment or participation in a research study concurrent with this study

NCT00680160
Pfizer
Completed
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Onychomycosis
NCT01278394
All Genders
18+
Years
Multiple Sites
Onychomycosis
NCT00679523
All Genders
18+
Years
Multiple Sites
Subungual Onychomycosis Distal
NCT00679770
All Genders
18+
Years
Multiple Sites
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis
The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25 otherwise healthy adult patients with onychomycosis.
For this study, the case definition of onychomycosis included moderate to severe distal subungual onychomycosis including subjects with evidence of subungual dermatophytoma or yellow spikes, lateral and proximal onychomycosis and severely dystrophic nail plates. Subjects with only superficial white onychomycosis were excluded. Confirmation of the clinical diagnosis of onychomycosis of at least one great toenail included a positive KOH wet mount.
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Onychomycosis
Drug: AN2690
AN2690 7.5% Solution, once daily for 28 days
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
May 2007
May 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • A witnessed, signed informed consent approved by Institutional Review Board
  • Male or female of any race at least 18 years of age but not older than 65 years of age at the time of screening
  • Body Mass Index between 18.5 and 35, inclusive
  • Onychomycosis involving > 80% of both great toenails, as determined by visual inspection after the nail has been trimmed
  • Each great toenail possess a combined thickness of the nail plate and nail bed > 3 mm
  • At least six additional toenails with clinical diagnosis of onychomycosis
  • A positive KOH wet mount for at least one great toenail
  • If subject is a female of childbearing potential, must be using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study
  • Considered reliable and capable of understanding his/her responsibility and role in the study

Exclusion Criteria:

  • History of allergy to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure
  • Clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety
  • Diabetes mellitus requiring treatment other than diet and exercise
  • Unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study
  • Nursing, pregnant or planning to become pregnant during the study
  • Has not undergone the specified washout period(s) for the following topical preparations or does the subject require the concurrent use of any of the following topical medications:

    1. Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study: 4 weeks
    2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
  • Has not undergone the specified washout period(s) for the following systemic medications or does the subject require the concurrent use of any of the following systemic medications:

    1. Corticosteroids (including intramuscular injections): 2 weeks
    2. Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophyte: 24 weeks
    3. Systemic immunomodulators: 4 weeks
  • Received treatment of any type for cancer within the last 6 months
  • History of any significant internal disease
  • Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated
  • AIDS or AIDS related complex
  • History of street drug or alcohol abuse
  • Donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation
  • Donated plasma during the two week period preceding study initiation
  • Participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00680160
AN2690-ONYC-202
No
Not Provided
Not Provided
Karl Beutner, MD, PhD, Chief Medical Officer, Anacor Pharmaceuticals, Inc.
Pfizer
Not Provided
Study Director: Karl Beutner, MD, PhD Pfizer
Pfizer
May 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now